<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284399</url>
  </required_header>
  <id_info>
    <org_study_id>OBX0032</org_study_id>
    <nct_id>NCT02284399</nct_id>
  </id_info>
  <brief_title>National Prevalence and Impact of Noninvasive Prenatal Testing</brief_title>
  <official_title>National Prevalence and Impact of Noninvasive Prenatal Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obstetrix Medical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Information on pregnant women undergoing non-invasive prenatal testing (NIPT) at one of the
      Obstetrix Medical Groups Outpatient Centers between January 2012 and June 2014 will be
      retrospectively gathered and an analysis of the impact and prevalence of NIPT. This will be
      compared to a control group of pregnant women in those same practices undergoing prenatal
      testing during the months of January 2010-July 2010.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information regarding the frequency of non-invasive testing (NIPT), the impact of screening
      on the need for and frequency of invasive testing, and the indications for testing are
      important for the clinicians in this country to not only understand the impact that this
      testing has had but also to plan for allocation of personnel and resources in their prenatal
      testing units, as well as many other more subtle changes including describing changes to
      referring clinicians and patients and projecting financial impacts. Information on pregnant
      women undergoing NIPT at one of the Obstetrix Medical Groups Outpatient Centers between
      January 2012 and June 2014 will be retrospectively gathered and compared to a control group
      of pregnant women in those same practices undergoing invasive prenatal diagnostic testing for
      fetal karyotype (IDTFK) during the months of January 2010-July 2010. An analysis of the
      impact of NIPT will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 28, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market</measure>
    <time_frame>4 years</time_frame>
    <description>Total Number of patient undergoing invasive diagnostic testing for fetal karyotype (IDTFK) before (control group = Jan - July 2010) and after (test group=Jan 2012-June 2014) NIPT testing came to market</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing.</measure>
    <time_frame>4 years</time_frame>
    <description>Will determine if frequency of positive tests for abnormal karyotypes between the control period and the study period where different.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4488</enrollment>
  <condition>Aneuploidy</condition>
  <arm_group>
    <arm_group_label>IDTFK Group Post NIPT - (January 2012-June 2014)</arm_group_label>
    <description>Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDTFK Group pre-NIPT (January 2010-July 2010)</arm_group_label>
    <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-invasive prenatal testing</intervention_name>
    <description>Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation</description>
    <arm_group_label>IDTFK Group Post NIPT - (January 2012-June 2014)</arm_group_label>
    <other_name>NIPT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women at participating Obstetrix Outpatient centers who are undergoing IDTFK
        between January 2012 and June 2014.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant Women

          -  Presented to a participating Obstetrix Outpatient Center for an invasive prenatal
             diagnostic testing for fetal karyotype (IDTFK) (i.e. amniocentesis or CVS).

          -  Invasive prenatal diagnostic testing for fetal karyotype (IDTFK) (i.e. amniocentesis
             or CVS) performed between January 2012 and June 2014 (A control group enrolled between
             January 2010 - July 2010)

        Exclusion Criteria:

          -  Patient less than 18 years of age

          -  Patients not receiving a invasive prenatal diagnostic testing for fetal karyotype
             (IDTFK)(i.e. amniocentesis or CVS) at a participating study center

          -  Testing NOT done within the window for inclusion (Jan 2012 - June 2014) or Control
             Group window (January 2010 - July 2010)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Maurel, MSN</last_name>
    <role>Study Director</role>
    <affiliation>Mednax Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Perinatal Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801-1428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian/St Luke's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Perinatal Associates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <results_first_submitted>May 15, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneuploidy</keyword>
  <keyword>Trisomy 21</keyword>
  <keyword>NIPT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IDTFK Group Pre-NIPT (January 2010-July 2010)</title>
          <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation.
Invasive Diagnostic testing for Fetal Karyotype (IDTFK) = Amniocentesis or chorionic villus sampling (CVS)</description>
        </group>
        <group group_id="P2">
          <title>IDTFK Group Post NIPT - (January 2012-June 2014)</title>
          <description>Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation.
Invasive Diagnostic testing for Fetal Karyotype (IDTFK) = Amniocentesis or CVS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1414"/>
                <participants group_id="P2" count="3074"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1414"/>
                <participants group_id="P2" count="3074"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IDTFK Group Post NIPT - (January 2012-June 2014)</title>
          <description>Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
        </group>
        <group group_id="B2">
          <title>IDTFK Group Pre-NIPT (January 2010-July 2010)</title>
          <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3074"/>
            <count group_id="B2" value="1414"/>
            <count group_id="B3" value="4488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3074"/>
                    <measurement group_id="B2" value="1414"/>
                    <measurement group_id="B3" value="4488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3074"/>
                    <measurement group_id="B2" value="1414"/>
                    <measurement group_id="B3" value="4488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for invasive test was Advance Maternal Age (AMA)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2071"/>
                    <measurement group_id="B2" value="996"/>
                    <measurement group_id="B3" value="3067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for invasive test was Family History of Aneuploidy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for invasive test was a Positive Serum Screening Test</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="995"/>
                    <measurement group_id="B2" value="499"/>
                    <measurement group_id="B3" value="1494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for invasive test was Ultrasound Abnormality noted</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="961"/>
                    <measurement group_id="B2" value="292"/>
                    <measurement group_id="B3" value="1253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for and invasive test was a Positive cell free DNA (cfDNA)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karyotype Results of Amniocentesis and CVS - Normal Result</title>
          <description>Note: percentages sum to more than 100% because some patient had more than one indication.</description>
          <population>Note: percentages sum to more than 100% because some patient had more than one indication.</population>
          <units>indications</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal karyotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2687"/>
                    <measurement group_id="B2" value="1310"/>
                    <measurement group_id="B3" value="3997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>47XXY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTHER</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for an invasive test was multifetal gestation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market</title>
        <description>Total Number of patient undergoing invasive diagnostic testing for fetal karyotype (IDTFK) before (control group = Jan - July 2010) and after (test group=Jan 2012-June 2014) NIPT testing came to market</description>
        <time_frame>4 years</time_frame>
        <population>This was an observational study that looked to compare the number of patient who underwent IDTFK during Jan 2010-July 2010 (prior to the adoption of NIPT) with the number of patients who underwent IDTFK during Jan 2012-June 2014 (after the adoption of NIPT).</population>
        <group_list>
          <group group_id="O1">
            <title>IDTFK Group Pre-NIPT (January 2010-July 2010)</title>
            <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
          </group>
          <group group_id="O2">
            <title>IDTFK Group Post NIPT - (January 2012-June 2014)</title>
            <description>Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market</title>
          <description>Total Number of patient undergoing invasive diagnostic testing for fetal karyotype (IDTFK) before (control group = Jan - July 2010) and after (test group=Jan 2012-June 2014) NIPT testing came to market</description>
          <population>This was an observational study that looked to compare the number of patient who underwent IDTFK during Jan 2010-July 2010 (prior to the adoption of NIPT) with the number of patients who underwent IDTFK during Jan 2012-June 2014 (after the adoption of NIPT).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1414"/>
                <count group_id="O2" value="3074"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1414"/>
                    <measurement group_id="O2" value="3074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing.</title>
        <description>Will determine if frequency of positive tests for abnormal karyotypes between the control period and the study period where different.</description>
        <time_frame>4 years</time_frame>
        <population>The number of positive tests identified between the control and the test periods.</population>
        <group_list>
          <group group_id="O1">
            <title>IDTFK Group Post NIPT - (January 2012-June 2014)</title>
            <description>Number of pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing procedure: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation</description>
          </group>
          <group group_id="O2">
            <title>IDTFK Group Pre-NIPT (January 2010-July 2010)</title>
            <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing.</title>
          <description>Will determine if frequency of positive tests for abnormal karyotypes between the control period and the study period where different.</description>
          <population>The number of positive tests identified between the control and the test periods.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3074"/>
                <count group_id="O2" value="1414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was an retrospective study. Adverse events were not captured</time_frame>
      <desc>This was an retrospective study. Adverse events were not captured</desc>
      <group_list>
        <group group_id="E1">
          <title>IDTFK Group Pre-NIPT (January 2010-July 2010)</title>
          <description>A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation.
Invasive Diagnostic testing for Fetal Karyotype (IDTFK) = Amniocentesis or CVS</description>
        </group>
        <group group_id="E2">
          <title>IDTFK Group Post NIPT - (January 2012-June 2014)</title>
          <description>Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
non-invasive prenatal testing: Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation.
Invasive Diagnostic testing for Fetal Karyotype (IDTFK) = Amniocentesis or CVS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Maurel</name_or_title>
      <organization>Mednax. Inc</organization>
      <phone>714-593-9171</phone>
      <email>kimberly_maurel@mednax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

